INTRODUCTION
The 20 kDa light chain of myosin in vertebrate non-muscle and smooth muscle cells is phosphorylated by a specific Ca2+/ calmodulin-dependent myosin light chain kinase (MLCK) [1, 2] . MLCK-mediated phosphorylation in these tissues is associated with an increase in the actin-activated MgATPase activity of myosin of greater than 100-fold [3, 4] and is a primary mechanism for initiation of contraction. Furthermore, in these cell types, myosin light chain is also known to be a substrate for the Ca2+/phospholipid-dependent protein kinase C (PKC). PKC incorporates phosphate into smooth muscle or non-muscle myosin light chain in vitro [5, 6] and in situ [7, 8] at sites that are distinct from the MLCK sites. PKC-mediated phosphorylation inhibits the increase in MgATPase activity associated with phosphorylation by MLCK [9] . The physiological significance of this phosphorylation, however, has not been clearly defined [10] .
In contrast to the case in smooth muscle, myosin phosphorylation in cardiac (and other striated) muscle is not an obligatory or initiating step in the activation of contraction [11] . Ca2+ activation ofcontraction in these tissues is, instead, mediated by the thin filament regulatory protein troponin. Cardiac myosin light chain (MLC2), however, is known to be phosphorylated in heart cells and a cardiac form of MLCK is also known to be present [12, 13] . In recent years, evidence has accumulated that MLC2 phosphorylation in myocardial cells may have a modulatory (as opposed to initiating) role in the regulation of contraction. For example, addition of exogenous MLCK and calmodulin to chemically skinned heart cells results in an increased Ca2+ sensitivity of force development [14] [15] [16] [17] and actomyosin MgATPase activity [17] , presumably due to phosphorylation of MLC2. Whether and when levels of light chain phosphorylation are altered in heart cells, however, has been a subject of controversy [18, 19] . Because MLCK is a Ca2+-activated enzyme, of MLC2 phosphorylation in these cells. 32P label is completely removed from MLC2 when myocytes are exposed to 2,3-butanedione monoxime, an inhibitor of cardiac contraction known to desensitize the myofilaments to activation by Ca2+. 32P labelling of MLC2 is also decreased by 50-1000% following exposure to the PKC-selective inhibitors calphostin C and chelerythrine, suggesting that PKC, and not MLCK, is primarily responsible for incorporation of rapidly turning over phosphate into MLC2 in situ. Taken together, these data implicate PKC in the phosphorylation of MLC2 in heart cells and support the hypothesis that phosphorylation of cardiac MLC2 has a role in determining myofibrillar Ca2+ sensitivity.
one might expect that increased phosphorylation of MLC2 would occur following elevation of cytoplasmic Ca2+ induced by positive inotropic agents. However, despite some reports that this does occur [20, 21] , many investigators have failed to observe any change in light chain phosphorylation upon perfusion of beating hearts with inotropic agents [22] [23] [24] . Thus it has been proposed that there may be insufficient MLCK activity in heart to cause a rapid rise in the overall level of light chain phosphorylation, even under conditions of increased cytoplasmic Ca2+ [25] .
For many years it has been assumed that MLCK is exclusively responsible for MLC2 phosphorylation in heart cells [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Recently, however, we have found that PKC incorporates phosphate stoichiometrically into MLC2 in cardiac myofibrils in vitro [26] . This Preparation of cardiac myofibrils and phosphorylation of myofibrils in vitro Cardiac myofibrils were prepared from adult rat hearts by homogenization and extraction with Triton X-100 as described by Murphy and Solaro [27] . PKC was purified from bovine brain as described previously and represents a mixture of PKC isoenzymes found in brain [28] . Myofibrils (20 ,g ) were incubated at 30°C for the times indicated in a reaction mixture (0.1 ml) containing 50 mM Tris/HCl, pH 7.5, at 30°C, 30 mM 2-mercaptoethanol, 10 mM MgCl2, 0.5 mM EGTA, 0.2 mM [y-32P]ATP (1000 c.p.m./pmol) and 1 mM sodium orthovanadate (to inhibit ATP depletion by the myofibrillar MgATPase activity). Phosphorylation with PKC (0.5 ,ug) was carried out in the presence or absence of 0.9 mM CaCl2, 50 ,ug/ml phosphatidylserine and 2 ,ug/ml diolein. Phosphorylation with skeletal muscle MLCK (0.1 ,ug) was carried out in the presence or absence of 0.9 mM CaCl2 and 20 ,ug/ml calmodulin. Phosphorylation was terminated by the addition of SDS sample buffer. 32P-labelled proteins were analysed by SDS/PAGE (5-15 % gradient gels) and autoradiography. In some experiments, radiolabelled MLC2 was excised from the gel and the 32P incorporated was quantified by liquid scintillation counting.
Isolatlon of cardlomyocytes and labelling of myofibrils in situ with [lP3Pp Cardiomyocytes were isolated from adult rat hearts by the collagenase perfusion method described by Kaku et al. [29] with minor modifications [26] . The viability of isolated cells was assessed by microscopic inspection and only cell suspensions of greater than 70 % viability were used in the experiments. Myocytes from a single heart were suspended in 10 ml of phosphate-free Dulbecco's minimum essential medium containing [32P]P1 (0.5 mCi/ml). Cells were incubated for 2 h at 37°C in 5 % CO2 humidified incubator. After a 2 h preincubation, aliquots (1 ml) of 32P-labelled cell suspension were further incubated for the times indicated in the presence of protein kinase inhibitors (chelerythrine, calphostin C or KT5926), a protein phosphatase inhibitor (calyculin A), or -a chemical dephosphorylating agent (BDM). Control incubations were performed by adding the reagent solvent (dimethyl sulphoxide) only. At the end of the incubation period, myofibrils were prepared as described previously [26] and solubilized in SDS sample buffer, and incorporation of 32P label into protein was analysed by SDS/PAGE and autoradiography. In some experiments, 32P label in MLC2 was quantified by liquid scintillation counting.
Analysis of site specifcity and stolchlonetry of MLC2 phosphorylatlon A cmparison of the sites phosphorylated in MLC2 in situ or in vitro 1y PKC and MLCK was carried out by two-dimensional tryptic phosphopeptide mapping under conditions described previously [26, 30] . 32P (spots 1 and 3) on two-dimensional maps (Figure 3a) . Trypsin digestion and mapping of the protein following phosphorylation by PKC in vitro generated what appear to be the same two phosphopeptides (Figure 3b ). Approx. 85% of the 32p label incorporated into MLC2 by PKC was present in the MLCK phosphopeptides (spots 1 and 3), with a lesser incorporation of label (15 %) into one or more additional sites (spots 5 and 6). A composite map (Figure 3c ) of a 1:1 mixture of the samples mapped in 3(a) and 3(b) further suggested that the major sites of phosphorylation in vitro may be the same for both MLCK and PKC. Phosphoamino acid analysis showed that incorporation of phosphate into MLC2 under these conditions by either MLCK or PKC occurred exclusively at phosphoserine residues (results not shown). [37] and KT5926 [38] . The effects of KT5926 and of the calmodulin antagonist calmidazolium [39] on in situ phosphorylation of MLC2 in cardiomyocytes were also examined. The selective inhibition of MLCK appeared not to be achieved in these experiments, however. Neither KT5926 nor calmidazolium inhibited MLC2 phosphorylation in situ, except when used at concentrations high enough to also inhibit TnI phosphorylation (suggesting nonselective effects of the inhibitors at these higher concentrations).
The site specificity of MLC2 phosphorylation in situ was analysed by two-dimensional tryptic phosphopeptide mapping. Basal (control) phosphorylation occurred almost exclusively in phosphopeptides 1 and 3 (Figure 5a ). These sites correspond to the major sites of phosphorylation by PKC in vitro (Figure 3b ) and to the only sites of phosphorylation by MLCK in vitro (Figure 3a) . However, in view of the significant inhibition of phosphorylation by the PKC-selective inhibitors chelerythrine and calphostin C (Figure 4) , we conclude that this basal sitespecific phosphorylation was catalysed primarily by PKC. Furthermore, phosphorylation by PKC in situ appears to occur almost exclusively at the sites phosphorylated in vitro by both PKC and MLCK (Figure 3) . A faint spot (spot 6) was also detected for phosphorylation in situ which corresponds to a minor site of phosphorylation by PKC in vitro. This phosphopeptide was never detected for MLC2 phosphorylated by MLCK in vitro. Calyculin A (10 nM) treatment of myocytes increased the 32p labelling of both major phosphopeptides (spots 1 and 3; Figure Sb) [45, 46] [49] as an explanation for why phorbol esters and aadrenergic agonists, both activators of PKC, can have opposite effects on cardiac contractility. These authors hypothesize that phorbol esters may activate all PKC isoenzymes present in heart, whereas a-adrenoreceptor agonists may activate only a specific subtype. In this regard, it is tempting to speculate that the known effect of a-adrenergic agonists in increasing cardiac myofibrillar Ca2+ sensitivity [50, 51] may occur, at least in part, through PKCmediated phosphorylation of MLC2.
